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Summary On 29 and 30 September 1983 Southampton hosted an invited Workshop sponsored jointly by the
Cancer Research Campaign and the British Association for Cancer Research. Workshop participants
discussed techniques for the phenotypic analysis of human lymphoma, the relationship of these cells to
normal lymphoid subpopulations and the value of this type of study in the staging of lymphoproliferative
disease. The presentations reported generated extensive discussion from all participants which it is not
possible to record in this brief report.
After first reviewing the pathways and interactions
associated with the activation of normal T-cells by
Interleukin (IL), A. Krajewski (Edinburgh) went on
to describe a study of leukaemic T-cells in terms of
production of and response to IL. There is
currently some doubt that the producers of human
IL-2 invariably belong to the helper/inducer
(OKT4+) subsets of T-cells. However, in the study
reported, all three OKT4+ T-cell - chronic
lymphocytic leukaemias (T-CLL) produced IL-2
when stimulated with phytohaemagglutinin (PHA).
In each case the mobility of the active molecule on
Sephadex G-100 paralleled that described for IL-2
by other authors. A single T-CLL of
suppressor/cytotoxic phenotype (OKT8+) did not
produce the growth factor following mitogenic
stimulation. All cases of OKT4+ and T-CLL gave a
good proliferative response in soft agar. When
stimulated with mitogen and IL-1 or IL-2, the
OKT8+ tumour responded only to IL-2 and PHA.
In each case the phenotype of the cells obtained
from colonies in agar corresponded to that of the
original neoplastic population. Proliferative
responses are not produced with highly purified
IL-2 alone, suggesting that growth factor and an
activation signal are required to induce
proliferation in T-CLL. The data suggest that in
the growth system studied T-cell leukaemia obeys
the rules described for normal T-cells.
Kaposi's Sarcoma (KS) has a high incidence in
many parts of tropical Africa. Considerable interest
has recently been prompted in the West by the
appearance of thiis tumour in individuals with the
Aquired Immunodeficiency Syndrome (AIDS) and
its relationship to Human T-cell leukaemia virus
(HTLV). R. Downing (Porton Down) has
investigated the incidence of antibodies to HTLV in
Zambian patients with KS and their associates. The
tumour shows geographical clustering in Africa and
in the adult form shows a marked male
preponderance. Local regression is sometimes seen
in adult KS. The childhood form of KS presents
with generalised lymphadenopathy and occurs with
equal frequency in both sexes. The disease in
patients with AIDS resembles this childhood form.
A high incidence of anti HTLV antibody has been
found in Zambian patients with KS and their
associates and it appears that HTLV may be
endemic in a part of Africa where KS is localised.
This result contrasts with the low incidence of anti
HTLV in associates of AIDS patients with KS. An
inversion in the normal T-helper/suppressor ratio,
considered diagnostic in AIDS is also seen in
Zambian KS patients. This finding may represent a
normal response to viral infection. Ambiguities exist
in the antibody assay employed for the
measurement of anti HTLV as considerable
homology exists between the genes coding for
HTLV envelope protein and Class I
histocompatibility products. This may, however,
point to a unifying hypothesis to account for the
different, apparently unrelated, groups known to
suffer from AIDS, many of whom are exposed to
alloantigen in some form.
High endothelial venules (HEV) in the paracortex
of lymph nodes are the site at which lymphocytes
pass from the blood stream into the node. Similar
vessels proliferate in T-cell lymphoma. R. Stoddart
(Manchester) described a detailed study of the
specialised characteristics of high endothelial cells
(HEV) present in cultured lymph node slices. The
cells show secretory activity and produce a
sulphated glycolipid, a soluble mucin-like
glycoprotein and an insoluble membrane-like
glycoprotein. It is clear that HEV are specialised
biochemically for glycosyl transfer. They appear to
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be largely anaerobic but retain the capacity to use
mitochondrial energy. The cells have no glycogen
and the absence of glucose-6-phosphate
dehydrogenase renders the pentose phosphate
pathway inoperable despite the presence of
transaldolase and transketolase activity.
Secretory activity is inhibited by prostaglandins,
in particular 6-Keto-PGF1,, whilst prostaglandins
with an 11-OH group slowly inhibit the process of
sulphate uptake. These secretory products may be
related to the role of HEV in lymphocyte traffic.
HEV have never been observed to divide and their
specialised function and morphology may be
induced in normal vascular endothelium by the
presence of lymphoblasts. HEV proliferation in
T-cell lymphoma and certain chronic inflammatory
states is consistent with this view.
The recent demonstration of distinct and separate
loci coding for various proteins of the Class II
histocompatibility system has stimulated
considerable interest in qualitative changes in the
distribution of these molecules in differentiation
and following neoplastic change. M. Steele
(Edinburgh) described original studies on the nature
and stimulating activity of Class II antigens in man.
EBV-transformed cell lines are good stimulators of
the autologous MLR, but no qualitative differences
in antigen expression can be detected on comparing
the cell lines with the donors' normal cells. The
autochthononous MLR does appear to be highly
dependent on Class II antigens since mutant
stimulator cells lacking some, or all, of the Class II
gene products are poor stimulators. The
distribution of Class II determinants on lymphoma
and leukaemia cells is as yet poorly investigated
though the development of monoclonal reagents
with good specificity for non-polymorphic Class II
determinants will advance our knowledge of this
area. Immunohistochemical studies have shown that
determinants defined by different monoclonal
antibodies to the same Class II molecule may be
differentially expressed within normal tissues. Data
obtained by surface staining of isolated cells or
frozen sections from leukaemia and lymphoma
patients imply that the Class II subloci SB, DR and
DC may be differentially expressed in these
conditions in a manner which is perhaps related to
development. Immaturity is marked by a high
expression of SB and a low expression of DC
determinants. It is necessary to interpret these data
carefully however, as cell line studies show that
subdeterminants may be randomly and variably lost
from individual cell lines. Finally, although
relationships between allelic specificities and
lymphoproliferative disease occur (90% of cases of
CLL in a recent New York study have MB3, a
DC allotype negatively associated with DR2 which
is shown to be under-represented in UK-CLL
patients) it is clear that the distribution and
expression of non-polymorphic determinants may
provide relevant observations that relate to
lymphoid cell differentiation and behaviour.
P. Aman (Stockholm) described in detail
experiments designed to identify the characteristics
of the B-cell population sensitive to transformation
by Epstein Barr (EB) virus. Density gradient
separation of B-lymphocyte subpopulations from
peripheral blood, tonsil and adenoid tissue reveal
that only high density (resting) B-cells are
susceptible to EBV transformation, as measured by
the appearance of EBV nuclear antigen (EBNA) at
48h. Low density (activated) B-cells are not
susceptible to EBV transformation and high density
cells that have become activated in culture are
similarly refractory. Both populations bind and
internalize labelled EBV. High density B-cells
successfully transformed with EBV themselves shift
to low density in culture; this change takes place
before EBNA appears. Data were also presented on
the phenotypic characteristics of the transformable
B-cells. Transformation is not restricted to cells
bearing either surface p or 5 chains, but it may be
that lymphocytes with surface y are resistent. The
monoclonal markers BBl and BB2, which identify
activated cells are absent from the target cell
population but appear on transformed cells. The
pan B-cell marker B-1 and the cell marker B-2 now
thought to identify the C3d receptor are present on
transformable cells. B-2 persists on EBV
transformed cells but not on control cells in culture.
It is often argued that tumours of the B-cell
series arise by transformation of progenitor cells.
This is clearly the case for common acute
lymphoblastic leukaemia and the lymphoblastic
form of chronic myeloid leukaemia. The evidence
that chronic lymphocyte leukaemia (CLL) arises
from an early B-cell within the bone marrow is less
persuasive. In their presentation on the clonogenic
cell in B-lymphocyte neoplasia L MacLennan and
N. Ling (Birmingham) described the events which
occur during lymphogenesis in adult bone marrow
and showed that phenotypically CLL does not
resemble any cell within this developmental series.
A fraction of the cells present among the small
lymphocytes of lymph nodes do, however, have a
phenotype which corresponds to CLL cells. The
pattern of distribution of CLL cells in secondary
lymphoid organs parallels that of immunologically
competent B-lymphocytes which recirculate in
healthy individuals. Dividing, neoplastic cells in this
disease are characteristically found at the
physiological sites for B-cell activation by antigen
in the lymph node. Antigen activated B-cells (or
immunoblasts) have three possible lines of
development: I) They may undergo terminal
maturation to plasma cells, 2) They may revert toPHENOTYPE AND STAGING IN HUMAN LYMPHOMA 253
small (memory) B-cells, 3) They may divide to give
further immunoblasts, a function which is limited
physiologically. Many of the forms of Non-
Hodgkin's Lymphoma (NHL) may represent
transformed activated B-cells which have an
unlimited capacity to produce daughter
immunoblasts. The morphological type of
lymphoma produced would depend on the extent to
which each of the differentiation pathways was
represented in the neoplastic cells. This scheme
would allow for mixed tumours. Similarly,
arguments can be made for differentiation from
centroblasts in follicle centre cell lymphoma. The
heterogeneity apparent within NHL and B-cell
leukaemia would depend therefore on the
differentiation potential of the clonogenic cells as
well as the B-cell subset in which it originated.
G. Janossy (London) presented additional
information on the heterogeneity of B-cell
populations in the lymphoid tissues. In particular
his group have examined foetal tissues where
development can occur without the complication of
antigenic stimulation. Foetal liver and bone marrow
(BM) are important haemopoietic organs; between
20% and 40% of the cells present being of the
lymphoid series. Of these, 30% are immature
types which lack surface IgM but have cytoplasmic
p chains and are TDT+. The remainder have a
more mature phenotype (TDT-, BA1+, surface,
,u+, ( ). A few intermediate forms are also present.
Additional B-cell antigens (Y29/55, Tol5, RFB-4)
are missing from the TDT+ cells but appear later
as stable markers of peripheral B-lymphocytes. In
intermediate cells antigens defined by these
antibodies may be seen in the cell cytoplasm. With
regard to the peripheral lymphoid organs, by 22
weeks primary follicles have formed with clusters of
B-cells (RF-2+ RF B-4+, ,+ , 3- Leu-l+)
surrounding follicular dendritic cells (DRC),
defined with appropriate monoclonal antibodies.
The DRC do not at this time have bound
complexes. Primary follicle formation is therefore
seen to be an event independent of antigen
exposure.
The formation of classical germinal centres, is an
antigen dependent process. The B-cells present in
these early follicles resemble B-CLL cells, and are
not represented in BM. Tissue cultures in the
presence of phorbol ester and cells of similar
phenotype extracted from normal tissues suggest
that these cells pass through a stage which
resembles hairy cell leukaemia on route to
becoming follicle mantle cells. Tartrate resistant
acid phosphatase is induced and in normal cells the
Leu-l marker is lost in favour of FMC7 and RFA-
4. (Neoplastic cells differ with regard to Leu-l).
Information of this type relating to normal cells is
of great value in our understanding of the nature
and behaviour of tumour cell populations. To
conclude the presentation simple protocols for the
characterisation of tumour cell populations
employing the Fluorescent Activated Cell Sorter
were described.
J. Habeshaw (London) has evaluated the
prognostic value of staining cells from non-
Hodgkin's lymphoma (NHL) biopsy specimens for
transferrin receptor (trf) identified by the OKT9
antibody. Trf is present on a mean of 5% of
reactive lymph node cells, with an upper limit of
15%. In lymphomas regarded as being of high
grade malignancy the percentage of OKT9+ cells is
generally higher with low grade lymphoma forming
an intermediate group. Within the high grade
lymphomas survival is inversely related to the
percentage ofOKT9+ cells present. The situation in
low grade NHL is less clear, but within this group
lymphocytic tumours generally exhibit a lower trf
level than lymphomas of follicle centre cell origin.
It would appear, therefore, that trf level can be used
in combination with histological grading to identify
lymphoma patients with a poor prognosis. Animal
models demonstrate that trf can be induced on the
surface of B-cells by IL-2, a product of activated T-
cells. Preliminary studies suggest that in the human
lymphoma series studied, biopsies with high OKT9
positivity contain a high percentage of T-cells
bearing an activation marker.
The controversial question of histiocytic
lymphoma was addressed by P. Isaacson (London).
Unlike the B-cell lymphomas, tumours of true
macrophage origin are poorly identified and
understood. One reason for this is the difficulty in
obtaining histiocytes from tissue biopsies. A major
problem concerns the phenotypic markers available.
Methods of analysis involving surface receptors
together with most of the currently available
monoclonal reagents identify blood monocytes and
reactive macrophages in preference to tissue
histiocytes, from which most lymphomas are
derived. The situation is further complicated by the
range of cells encompassed within the
"macrophage-monocyte series" which include
various types of dendritic cell (antigen presenting
cells), epithelioid cells and other reticuloendothelial
types. This heterogeneity is compounded by the fact
that individual macrophage populations change
their phenotypic characteristics following activation.
It is clear that with careful immunohistochemical
techniques using conventional antisera to
components of the macrophage cytoplasm (alpha 1
anti trypsin, alpha 1 anti chrymotrypsin and rarely
lysozyme) together with certain specific antisera
(some developed in Southampton) permit the
identification and characterisation of a group of
true histiocytic lymphomas. Two cases presented,
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occasionally be contradictory and that a full
appreciation of the lymphomas of this lineage must
await the development of superior markers and
improved understanding of the normal cell lineage.
The origin of the Reed Stemnberg (RS) cell
remains an area of controversy. Previous
hypotheses have considered this cell to be derived
from lymphocytes, histiocytes or antigen presenting
(dendritic) cells, H. Stein (Berlin) began his
discussion of this topic with a definition of
Hodgkins disease (HD) which stressed the
importance of the correct tissue background as well
as the presence of RS and Hodgkins cells (HC) in
the diagnosis of this condition. Careful analysis of
RS and HC populations in frozen tissue with a
range of monoclonal antibodies shows that they
cannot be placed within any known cell lineage.
The recent development in Germany and
Southampton of cell lines of neoplastic karyotype
from HD has shed new light on the RS/HC lineage.
The cultured cell lines have a phenotype which
corresponds closely to the pattern of staining seen
on RS and HC in frozen sections. One particular
monoclonal antibody (Ki-1) raised to the surface of
the L428 cell line stains RS and HC cells, other HD
cell lines and a unique population of cells found in
the perifollicular area of lymph nodes and tonsils.
This cell may be the normal counterpart of RS and
HC cells.
Supernatants of the L428 cell line have been
shown to exhibit lymphokine-like activity an
observation relevant to the development of the
reactive stroma in HD. The Southampton cell line,
which resembles L428 and carries the Ki-l antigen,
has also been shown to exhibit an isoenzyme
pattern for non-specific esterase which is
uncharacteristic of any other cell type examined,
(D.B. Jones, Southampton and S. Scott, Leeds). This
result further suggests that RS and HC cells
represent a unique cell lineage.
P. Beverley (London) provided cautionary data
on the use of monoclonal antibodies in defining
T-cells which complemented earlier comments on
cells of the macrophage lineage. It is clear from
studies of normal cell populations that phenotype
may vary both through development and after
neoplastic transformation. The physiological
environment in which a cell exists may also affect
phenotype. A cloned T-cell line responsive to P20,
an antigen derived from influenza virus
haemagglutinin, shows increased levels of an
activation marker after binding of P20. The level of
T3 antigen expression (T-cell receptor associated
antigen) is reduced however. In other cases the
marker is expressed but not functional.
It is also clear that even with monoclonal
antibodies suprising cross reactivities can occur.
The antibody UCHT1, raised to peripheral blood
lymphocytes, is a valuable reagent for the
identification of benign or neoplastic T-cells in
biopsy tissue. In the brain Purkinje cells and their
processes stain heavily with this antibody. The
molecule recognised by UCHT1 in Purkinje cells is
probably different from that recognised on T-cells.
Within the lymphoid system antibodies which
identify the inducer subset in suspension often stain
the cytoplasm of macrophages. These observations
indicate that monoclonal antibody data on
pathological specimens should be interpreted with
care and always with regard to the behaviour of
normal cell populations.
Idiotype represents one of the most specific of
known differentiation antigens. Attack on the
tumour idiotype should result in specific damage to
the neoplastic population with minimum injury to
the normal lymphoid cells. G.T. Stevenson
(Southampton) outlined his experience with anti
idiotype therapy. At present certain limitations to
effective therapy exist. Exported idiotypic
immunoglobulin may produce a barrier which
prevents antibody binding to tumour cells and the
expression of idiotypic determinants may be
modulated by bound antibody. Studies in vitro and
in the L2C guinea pig leukaemia model show that
univalent antibody derivatives offer promise in
avoiding antigenic modulation. These may be
constructed in various ways but have in common
the retention of the immunoglobulin Fc region. An
additional problem is that as yet we do not
understand the relative usefulness of the various
effector mechanisms which may be initiated by
bound idiotype.
The diagnosis of bone marrow involvement is an
important part of the staging of lympho-
proliferative disease. F. Pizzolo (Verona) described
an evaluation of immunohistochemical techniques
in identifying lymphoma cells in bone marrow.
Morphological analysis of bone marrow aspirates
or trephine biopsies are relatively insensitive as
methods of detecting neoplastic cells.
Immunohistochemical techniques have improved on
both these methods. Despite certain technical
problems associated with frozen trephine material,
e.g., the presence of fat, bony trabeculae and
peroxidase rich haemopoietic elements, it is now
possible to routinely stain sections of marrow
trephines with a panel of monoclonal and
conventional antibodies. Difficulties may be
experienced in the definition of monoclonal
populations using antibodies to immunoglobulin.
Double staining using reagents labelled with two
fluorochromes may be useful in the precise
identification of unusual tumour cells and minority
populations can also be readily identified with
appropriate antibodies in marrow infiltrates. The
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understanding of lymphoproliferative disease were
shown in a study of B-CLL. Immunohistochemical
methods clearly identify the pattern of involvement
with neoplastic cells as either nodular or diffuse
and further show that the phenotype of the CLL
cells is constant in blood and tissue. However,
infiltrating T-cells present alongside the neoplastic
population differ between blood and marrow. T-
lymphocytes of inducer phenotype predominate in
the marrow; the reverse of the situation in blood.
This observation may be of pathophysiological
significance.
Data on marrow involvement were also presented
by J. Smith (Southampton) who described the
results of a study of blood and marrow
involvement in Non-Hodgkin's Lymphoma (NHL)
patients in the Medical Oncology Trial Group. A
total of 184 NHL patients have been assessed by
the Lymphoma Study Group and phenotypic
analysis of blood and marrow is available for 107
of these. It is clear that immunological methods
greatly improve the sensitivity of diagnosis of
marrow involvement when compared with either
cytological analysis of marrow aspirates (53%
positive in comparison with 18%) or with the
histological examination of trephine biopsies (33%).
Monoclonal B-cell populations can also be readily
identified in the blood in NHL of low and high-
grade malignancy. The analysis of survival data for
patients with high grade malignancy shows that the
immunological investigation of the bone marrow
provides information of value in staging and for
prognostic purposes.
In summary phenotypic analysis of tumour cells
is of value in the diagnosis and staging of
lymphoproliferative disease. Comparison with the
behaviour of the appropriate normal populations
can give important clues to the behaviour of
tumour cells and extranodal involvement can be
readily identified. The identification and
localisation of accessory cell populations is
important in this respect. Problems still exist
however. Firstly, we do not yet know enough about
the differentiation and behaviour of many of the
normal lymphoid cells to make clear statements
about origin and behaviour in some lymphomas.
The relevance of some of the markers defined by
monoclonal antibodies is not yet clear and the data
on tumours must be interpreted with caution.
Finally, in some lineages appropriate markers do
not yet exist to define tumour populations.
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